阿帕替尼治疗原发和复发胶质瘤的不良反应差异性分析  

Differential analysis of adverse reactions between primary and recurrent gliomas treated with apatinib

作　　者：毛冲冲[1] 张庆浩 冯亚文[1] 赵海彪 刘献志[1] Mao Chongchong;Zhang Qinghao;Feng Yawen;Zhao Haibiao;Liu Xianzhi(Department of Neurosurgery,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450000,China)

机构地区：[1]郑州大学第一附属医院神经外科,郑州450000

出　　处：《中华实验外科杂志》2024年第9期1949-1951,共3页Chinese Journal of Experimental Surgery

摘　　要：目的 探究阿帕替尼在治疗原发及复发胶质瘤时出现各类不良反应是否存在差异及其剂量相关性.方法 本研究纳入2016年8月至2019年9月在郑州大学第一附属医院接受阿帕替尼治疗的103例脑胶质瘤患者并进行回顾性分析,获取患者临床资料、阿帕替尼应用方案及不良反应情况.卡方检验和Logistic回归用于挖掘独立相关因素.结果 103例应用阿帕替尼的患者中共有44例出现不同类型的不良反应,主要包括血压升高16例(15.53%)、手足综合征11例(10.68%)、胃肠道反应10例(9.71%)等,这些不良反应在复发胶质瘤中出现的频率[47.19%(42/89)]高于原发胶质瘤[14.29%(2/14)],且差异有统计学意义(P<0.05).阿帕替尼不良反应的出现及类别与服用剂量无明显相关性(P>0.05).结论 阿帕替尼在治疗原发及复发胶质瘤时出现不良反应存在明显差异,但未发现存在剂量相关性.Objective To investigate whether there are differences in the various complications of apatinib in the treatment of primary and recurrent gliomas,as well as its dose correlation.Methods This study concluded 103 patients with glioma who received apatinib treatment at the First Affiliated Hospital of Zhengzhou University from August 2016 to September 2019 and a retrospective analysis was conducted.The complications were analyzed.T-test and logistic regression were used to explore independent related factors.Results Among 103 patients who received apatinib,a total of 44 cases experienced different types of ad-verse reactions,mainly including elevated blood pressure 16 cases(15.53%),hand foot syndrome 11 ca-ses(10.68%),gastrointestinal reactions 10 cases(9.71%),etc.The frequency of these adverse reac-tions in recurrent gliomas[47.19%(42/89)]was significantly higher than that in primary gliomas[14.29%(2/14),P<0.05].The occurrence and category of adverse reactions to apatinib were not sig-nificantly correlated with the dosage taken(P>0.05).Conclusion There were significant differences in the adverse reactions of apatinib in the treatment of primary and recurrent gliomas,but no dose correlation was found.

关 键 词：胶质瘤 阿帕替尼 并发症 

分 类 号：R739.41[医药卫生—肿瘤]